Compare Noble Corporation plc (NE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Noble Corporation plc vs TG Therapeutics Inc — how do they compare? Noble Corporation plc trades at $42.53 (market cap $6.48B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and Noble Corporation plc pays a 4.93% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NE | TGTX | |
|---|---|---|
Market Cap | $6.48B | $8.26B |
Sector | Technology | Health |
52-Week High | $54.37 | $59.06 |
52-Week Low | $25.70 | $26.39 |
Enterprise Value | $7.73B | $8.50B |
Dividend Yield | 4.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Noble Corporation (NE) trades at $40.60, down 2.17% on the day, with a neutral technical signal. The company reported mixed Q1 2026 earnings, beating expectations, but missed in the prior two quarters. Recent news highlights new offshore drilling contracts, including a $136.2 million Brunei deal, and the upcoming Q2 2026 earnings report on July 27, 2026. Positive cash flow and a dividend payment of $0.50 per share in June 2026 support shareholder returns.
The outlook is cautiously optimistic, supported by new contracts and a consensus price target of $49.75, implying potential upside. Risks include execution on earnings expectations and offshore drilling market volatility. Analyst sentiment is mixed, with 31% Buy ratings, but the stock's current price is near the low end of the target range, suggesting a balanced risk-reward profile.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
